Crispr Therapeutics Ag Earnings

Crispr Therapeutics Ag’s revenue fell -82.5% since last year same period to $35Mn in the Q4 2024. On a quarterly growth basis, Crispr Therapeutics Ag has generated 5713.95% jump in its revenue since last 3-months.

Crispr Therapeutics Ag’s net profit fell -141.76% since last year same period to $-37.31Mn in the Q4 2024. On a quarterly growth basis, Crispr Therapeutics Ag has generated 56.59% jump in its net profits since last 3-months.

Crispr Therapeutics Ag’s net profit margin fell -338.63% since last year same period to -106.6% in the Q4 2024. On a quarterly growth basis, Crispr Therapeutics Ag has generated 99.25% jump in its net profit margins since last 3-months.

Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current quarter stand at -1.19 - a 16.51% jump from last quarter’s estimates.

Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current year stand at -1.19.

Crispr Therapeutics Ag’s earning per share (EPS) fell -140% since last year same period to -0.44 in the Q4 2024. This indicates that the Crispr Therapeutics Ag has generated -140% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Crispr Therapeutics Ag’s return on assets (ROA) stands at -0.13.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Crispr Therapeutics Ag’s return on equity (ROE) stands at -0.19.